Trial Profile
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Lenalidomide; Melphalan; Thalidomide
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TOURMALINE-AL1
- Sponsors Takeda Oncology
- 25 Aug 2023 The protocol has been amended as above-1) Number of treatment arms has been changed from 2 to 5. 2) Primary endpoints has been amended.
- 01 May 2023 Results published in the American Journal of Hematology
- 02 Nov 2022 This trial has been completed in Germany (End Date: 11 July 2022) according to European Clinical Trials Database record